A Pilot Study of SGT-53 in Conjunction With Irradiation and Chemotherapy in Children With Recurrent or Progressive CNS Malignancies
Status: Not yet recruiting
Phase of Trial: Phase 0
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs SGT 53 (Primary) ; Bevacizumab; Irinotecan; Temozolomide
- Indications CNS cancer
- Focus Adverse reactions
- Sponsors SynerGene Therapeutics
- 06 Aug 2019 Last checked against ClinicalTrials.gov record.
- 02 Aug 2019 Planned End Date changed from 1 Mar 2020 to 1 Dec 2020.
- 02 Aug 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2020.